



Interview Summary	Application No.	Applicant(s)	
	09/770,901	FAOUR ET AL.	
	Examiner	Art Unit	
	Shaojia A Jiang	1617	

All participants (applicant, applicant's representative, PTO personnel):

(1) Shaojia A Jiang.

(2) Padmanabhan, Sreeni.

(3) Rick Matos 
 (4) GLENN A. MEYER 

Date of Interview: 2/23/04

Type: a) ☐ Telephonic b) ☐ Video Conference
 c) ☒ Personal [copy given to: 1) ☐ applicant 2) ☒ applicant's representative]

Exhibit shown or demonstration conducted: d) ☒ Yes e) ☐ No.

If Yes, brief description: _____

Claim(s) discussed: all claims

Identification of prior art discussed: the cited prior art

Agreement with respect to the claims f) ☐ was reached. g) ☒ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: _____

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

- Applicant would consider to file RCE to narrow the instant claims to overcome the 112-1st scope of enablement rejections.

- Applicant explained the unexpected result for the combination of rofecoxib + prindinol diclofenac + prindinol.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

SEJ 2/23/04
 Examiner's signature, if required

Table 2: Contortions per 10 minutes for the combination of diclofenac sodium and rofecoxib and pridinol.

Diclofenac Plus Pridinol						
Dose (mg/kg)		Contortions per 10 minutes in each mouse				
0.0 (Normal saline)		14	14	35	7	19
16		12	26	20	7	9
32		25	15	15	11	12
64		20	12	9	21	25
						12
Mean	S.D.					
		17.8				12.1
		13.0				8.4
		19.2				6.0
		16.5				5.9


Rofecoxib Plus Pridinol						
Dose (mg/kg)		Contortions per 10 minutes in each mouse				
0.0 (1% CMC)		33	43	44	56	37
16		33	7	20	28	13
32		28	37	25	29	15
64		18	29	13	29	11
						20
Mean	S.D.					
		40.8				8.9
		7				9.9
		28				7.9
		13				8.6

Table 3: Two tailed T-Test statistical analysis of the combination of diclofenac & pridinol versus rofecoxib & pridinol

Diclofenac Plus Pridinol		P value from Control
Dose (mg/kg)		
0.0 (Normal saline)		
16	0.4208	
32	0.8308	
64	0.8054	

Rofecoxib Plus Pridinol		P value from Control
Dose (mg/kg)		
0.0 (1% CMC)		
16	0.0001	
32	0.0012	
64	0.0001	

Diclofenac Plus Pridinol



Rofecoxib Plus Pridinol

